These results provide justification for use of this cutoff to identify an important minority of patients with ER-positive, HER2 negative, node-negative early breast cancer who are at high risk for distant recurrences without chemotherapy, and who should be offered chemotherapy to substantially reduce the risk of distant recurrences. This evidence concerns the gene ESR1 and breast cancer.